Therapeutic | Lampalizumab |
Target | CFD |
Heavy Chain | EVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGWINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSS |
Light Chain | DIQVTQSPSSLSASVGDRVTITCITSTDIDDDMNWYQQKPGKVPKLLISGGNTLRPGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCLQSDSLPYTFGQGTKVEIK |
100% seqID Fv Structure | 4d9q [Fvs: ED, HL], 4d9r [Fvs: ED, HL] |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
100% seqID Structure | 4d9q [Fvs: ED, HL] |
100% seqID Structure | 4d9r [Fvs: ED, HL] |
Follow these links to our prediction tools:
Format | Fab |
Isotype | G1 |
Highest Clinical Trial (June '19) | Phase-III |
Estimated Status (June '19) | Discontinued |
Recorded Developmental Technology | na |
INN Year Proposed | 2012 |
INN Year Recommended | 2013 |
Companies Involved | Tanox, Genentech |
Conditions Approved | na |
Conditions Active | na |
Conditions Discontinued | Dry age-related macular degeneration |
Notes |